Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Operations (2016 - 2025)

Ani Pharmaceuticals' Cash from Operations history spans 16 years, with the latest figure at 30367000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 91.47% year-over-year to 30367000.0; the TTM value through Dec 2025 reached 185225000.0, up 189.34%, while the annual FY2025 figure was 185225000.0, 189.34% up from the prior year.
  • Cash from Operations for Q4 2025 was 30367000.0 at Ani Pharmaceuticals, down from 44055000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 75812000.0 in Q2 2025 and bottomed at 18942000.0 in Q1 2022.
  • The 5-year median for Cash from Operations is 17841500.0 (2024), against an average of 17016000.0.
  • The largest annual shift saw Cash from Operations crashed 4865.15% in 2022 before it skyrocketed 1116.82% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 12185000.0 in 2021, then skyrocketed by 63.89% to 4400000.0 in 2022, then surged by 1116.82% to 44740000.0 in 2023, then tumbled by 64.55% to 15860000.0 in 2024, then soared by 91.47% to 30367000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Cash from Operations are 30367000.0 (Q4 2025), 44055000.0 (Q3 2025), and 75812000.0 (Q2 2025).